TORONTO, July 24 /CNW/ - Patheon Inc. (TSX: PTI) today announced that,
based on its latest forecast, it expects to report a net loss of between 8 and
10 cents per share (before any one-time items) for its third quarter ending
July 31, 2006. The Company expects to report between $12 and $14 million of
EBITDA (earnings before depreciation and amortization, interest, debt pre-
payment charges, write-off of deferred financing costs and income taxes) in
the quarter. (All amounts are in U.S. dollars unless otherwise indicated.)
Revenues and EBITDA have been adversely affected by Patheon's actions
after it identified a concern through routine testing that, in certain
circumstances, some batches of a product manufactured in Patheon's Caguas
facility in Puerto Rico might not achieve their expected shelf life. The
Company decided not to release any more product at that time and to
temporarily stop production while it evaluated and put in place corrective
measures. After considering various potential causes and solutions, Patheon
and its client, who owns the product, developed a modified production process
and production has recommenced with this process. The Company expects that,
prior to the end of August, the Company and the client will be able to review
the results of the new production process to determine whether it has
successfully addressed the concern. If the results are not clear and if no
product is shipped during the fourth quarter, the negative impact to EBITDA
would be approximately $5 million in the fourth quarter.
Revenues and EBITDA in the third quarter were also adversely affected by
a temporary disruption in the supply of an ingredient for a different product
manufactured at another of the Puerto Rican facilities, which did not disrupt
the client's inventory situation. That situation has now been remedied.
The impact of these and other factors in our Puerto Rican operations are
expected to cause a decline in EBITDA of more than $9 million in the third
quarter of 2006 compared with the third quarter of 2005.
As a result of these developments and the current view of Patheon's
operations throughout the network for the balance of the fiscal year, the
Company expects that revenues for the second half of 2006 will be similar to
revenues in the second half of 2005 and that EBITDA will be significantly
lower than in the second half of 2005.
"In light of these results, we will accelerate our performance
enhancement program launched last quarter and this will include a
comprehensive review of all the Company's operations and its financing
structure. We have engaged external advisors to help with this shareholder-
value enhancement program," said Peter Green, Chairman of the Board and a
member of the Office of the Chief Executive.
The Company has commenced discussions with the lenders under its North
American credit facilities to amend certain financial covenants provided for
in those facilities, in light of these financial results and to provide for
greater financial flexibility as it implements its performance enhancement
program. Under this credit agreement the Company has revolving credit
facilities of $75 million, of which approximately $17 million was drawn as of
July 21, 2006.
About Patheon
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 6,100 people and serving a client base
of more than 200 pharmaceutical and biotechnology companies.
Use of Non-GAAP Measures
Except as otherwise indicated, references to "EBITDA" are to earnings
before depreciation and amortization, interest, debt prepayment charges,
write-off of deferred financing costs and income taxes. EBITDA is a measure of
earnings not recognized by generally accepted accounting principles in Canada
("Canadian GAAP"). Since this measure is a non-GAAP measure that does not have
a standardized meaning, it may not be comparable to similar measures presented
by other issuers. Readers are cautioned that EBITDA should not be construed as
an alternative to net earnings determined in accordance with Canadian GAAP as
indicators of performance. The Company has included this measure because it
believes that this information is used by certain investors to assess
financial performance.
Forward-Looking Statements
This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.
%SEDAR: 00001700E